Sparrow Pharmaceuticals to Present on HSD-1 Inhibitor HSD-1 Inhibitor SPI-62 at Endocrine Society 2023 Annual Conference

2023-06-08

临床2期临床1期

The company invites visitors to booth #1949 to discuss its mission and clinical programs PORTLAND, Ore.--(BUSINESS WIRE)-- Sparrow Pharmaceuticals, an emerging, clinical-stage biopharmaceutical company developing novel, targeted therapies to address unmet needs in both endocrinology and rheumatology, will present the rationale that its lead candidate and HSD-1 inhibitor HSD-1 inhibitor, SPI-62, is predicted to be associated with limited adrenal insufficiency risk in Cushing’s syndrome during a poster session at the Endocrine Society (ENDO) 2023 Annual Conference. The meeting will be held in-person from June 15-18, 2023 in Chicago, IL. Presentation title: Intracellular Cortisol Control: An Approach to Reduce Cushing’s Syndrome Morbidity With Minimal Adrenal Insufficiency Risk? Presenters: Frank S. Czerwiec, MD, PhD, Chief Medical Officer at Sparrow Pharmaceuticals; David A. Katz, PhD, Chief Scientific Officer, Sparrow Pharmaceuticals; Paul M. Stewart, MD, FRCP, FMedSci, University of Leeds, UK Presentation number: SAT-281 Session Category: P71 - Clinical Adrenal & Pituitary: Adrenal Basic Science/Animal Models Date: Saturday, June 17, 2023 at 1:00pm-2:00pm CT Sparrow is also available to connect with attendees at the company’s booth (#1949) during regular exhibit hours to learn more about Sparrow’s mission and clinical programs. SPI-62 is a potent HSD-1 inhibitor HSD-1 inhibitor in clinical development for treatment of Cushing’s syndrome and autonomous cortisol secretion, and as adjunctive therapy to prednisolone in polymyalgia rheumatica. In prior Phase 1 and Phase 2 clinical trials, SPI-62 was associated with maximal liver, adipose, and brain HSD-1 inhibition at generally well tolerated doses. To learn more about Sparrow Pharmaceuticals SPI-62, visit . About Sparrow Pharmaceuticals Sparrow Pharmaceuticals was founded to spare patients the ravages of steroids. Leveraging underappreciated scientific insights into glucocorticoid biology, the company is working to provide better treatment options for serious disorders of hypercortisolism, and to revolutionize the treatment of autoimmune and inflammatory conditions. Its lead product, SPI-62, is an oral, small molecule, novel therapeutic treatment designed to target the source of active intracellular glucocorticoids in key tissues.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构